Ablynx Announces Results of Phase I Study of ALX-0081

Ablynx announced positive interim results from the ongoing Phase I study of its lead development program, ALX-0081, an antithrombotic treatment.

According to Ablynx, ALX-0081 was designed to reduce the risk of thrombosis in patients with acute coronary syndrome.

The Phase I study in healthy volunteers is designed to assess safety, tolerability and pharmacokinetics of ALX-0081. It will also analyze pharmacodynamic effects of ALX-0081 to confirm its high potency, the company said.

Interim data from the single-center, double-blind, placebo-controlled trial show that the desired pharmacodynamic effect was observed as anticipated, indicating the high potency of ALX-0081, and that ALX-0081 was well-tolerated and showed no serious adverse effects or dose-limiting toxicity, the company said.

The final results are anticipated to be available by the end of September.